Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons

A role for glucagon-like peptide-1 in the central regulation of feeding

Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950

Differential expression of orexin receptors 1 and 2 in the rat brain

Marcus, J. N., Aschkenasi, C. J., Lee, C. E., Chemelli, R. M., Saper, C. B., Yanagisawa, M., & Elmquist, J. K. (2001) · Journal of Comparative Neurology · doi:10.1002/cne.1190 · Cited by 1,659

Direct hypothalamo-autonomic connections

Saper, C. B., Loewy, A. D., Swanson, L. W., & Cowan, W. M. (1976) · Brain Research · doi:10.1016/0006-8993(76)90738-1 · Cited by 1,199

Immunohistochemical identification of neurons in the paraventricular nucleus of the hypothalamus that project to the medulla or to the spinal cord in the rat

Sawchenko, P. E., & Swanson, L. W. (1982) · Journal of Comparative Neurology · doi:10.1002/cne.902050306 · Cited by 1,150

Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells.

Göke, R., Fehmann, H. C., Linn, T., Schmidt, H., Krause, M., Eng, J., & Göke, B. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)36565-2 · Cited by 837

Leptin Activates Hypothalamic CART Neurons Projecting to the Spinal Cord

Elias, C. F., Lee, C., Kelly, J., Aschkenasi, C. J., Ahima, R. S., Couceyro, P. R., Kuhar, M. J., Saper, C. B., & Elmquist, J. K. (1998) · Neuron · doi:10.1016/s0896-6273(00)80656-x · Cited by 809

A functional anatomical analysis of central pathways subserving the effects of interleukin-1 on stress-related neuroendocrine neurons

Ericsson, A. B., Kovacs, K., & Sawchenko, P. E. (1994) · Journal of Neuroscience · doi:10.1523/jneurosci.14-02-00897.1994 · Cited by 679

Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem

Larsen, P. J., Tang-Christensen, M., Holst, J. J., & Ørskov, C. (1997) · Neuroscience · doi:10.1016/s0306-4522(96)00434-4 · Cited by 663

Glucagon-Like Peptides

Drucker, D. J. (1998) · Diabetes · doi:10.2337/diab.47.2.159 · Cited by 598

A general pattern of CNS innervation of the sympathetic outflow demonstrated by transneuronal pseudorabies viral infections

Strack, A. M., Sawyer, W. B., Hughes, J., Platt, K. B., & Loewy, A. D. (1989) · Brain Research · doi:10.1016/0006-8993(89)90098-x · Cited by 591

Effects of Glucagon-Like Peptide-1 Receptor Agonists on Hypothalamic-Pituitary-Adrenal Axis in Healthy Volunteers

Winzeler, B. F., da Conceição, I., Refardt, J. C., Sailer, C. O., Dutilh, G., & Christ‐Crain, M. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01420 · Cited by 18

Glucagon-like peptide-1 (7–36) but not (9–36) augments cardiac output during myocardial ischemia via a Frank–Starling mechanism

Goodwill, A. G., Tune, J. D., Noblet, J. N., Conteh, A. M., Sassoon, D., Casalini, E. D., & Mather, K. J. (2014) · Basic Research in Cardiology · doi:10.1007/s00395-014-0426-9 · Cited by 18

Harnessing the incretin system beyond glucose control: Potential cardiovascular benefits of GLP-1 receptor agonists in type 2 diabetes

Cariou, B. (2012) · Diabetes & Metabolism · doi:10.1016/j.diabet.2012.04.003 · Cited by 18

Cardiovascular side-effects and insulin secretion after intravenous administration of radiolabeled Exendin-4 in pigs

Rydén, A., Nyman, G. C., Nalin, L., Andréasson, S., Korsgren, O., Eriksson, O., & Jensen‐Waern, M. (2016) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2016.04.002 · Cited by 18

Exendin‑4 inhibits atrial arrhythmogenesis in a model of myocardial infarction‑induced heart failure via the GLP‑1 receptor signaling pathway

Chen, J., Xu, S., Wang, L., Zhou, W., Li, P., Deng, N., Tang, Q., Li, Y., Wu, L., Chen, J., et al. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.9089 · Cited by 17

Cardiovascular and hemodynamic effects of glucagon-like peptide-1

Goodwill, A. G., Mather, K. J., Conteh, A. M., Sassoon, D., Noblet, J. N., & Tune, J. D. (2014) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-014-9290-z · Cited by 17

Multifactorial intervention in Type 2 diabetes: The promise of incretin-based therapies

Giorgino, F., Leonardini, A., Natalicchio, A., & Laviola, L. (2011) · Journal of Endocrinological Investigation · doi:10.1007/bf03346698 · Cited by 17

Heart rate variability in type 2 diabetic subjects randomized to liraglutide or glimepiride treatment, both in combination with metformin: A randomized, open, parallel‐group study

Nyström, T., Santos‐Pardo, I., Fang, X. L., Cao, Y., Hedberg, F., & JENDLE, J. H. (2019) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.58 · Cited by 17

Incretin Therapies: Effects Beyond Glycemic Control

Mudaliar, S. R. D., & Henry, R. R. (2009) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2009.05.010 · Cited by 18

Cyclooxygenase-1 and -2 in spinally projecting neurons are involved in CRF-induced sympathetic activation

Yamaguchi, N., & Okada, S. (2009) · Autonomic Neuroscience · doi:10.1016/j.autneu.2009.06.009 · Cited by 17

Elevated blood pressure, heart rate and body temperature in mice lacking the XLαs protein of the Gnas locus is due to increased sympathetic tone

Nunn, N., Feetham, C. H., Martin, J., Barrett‐Jolley, R., & Plagge, A. (2013) · Experimental Physiology · doi:10.1113/expphysiol.2013.073064 · Cited by 17

Preclinical and Clinical Data on Extraglycemic Effects of GLP-1 Receptor Agonists

Gallwitz, B. (2009) · The Review of Diabetic Studies · doi:10.1900/rds.2009.6.247 · Cited by 17

The Presympathetic Cells of the Rostral Ventrolateral Medulla (RVLM): Anatomy, Physiology and Role in the Control of Circulation

Guyenet, P. G., & Stornetta, R. L. (2004) · Springer eBooks · doi:10.1007/978-1-4419-9054-9_9 · Cited by 17

Cacao polyphenols regulate the circadian clock gene expression and through glucagon-like peptide-1 secretion

Hironao, K.-Y., Mitsuhashi, Y., Huang, S., Oike, H., Ashida, H., & Yamashita, Y. (2020) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.20-38 · Cited by 18

The incretin system and cardiometabolic disease

Szmitko, P. E., Leiter, L. A., & Verma, S. (2010) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(10)70010-6 · Cited by 17

Evidence for Relationship Between Early Dumping and Postprandial Hypoglycemia After Roux-en-Y Gastric Bypass

Øhrstrøm, C. C., Worm, D., Kielgast, U. L., Holst, J. J., & Hansen, D. L. (2020) · Obesity Surgery · doi:10.1007/s11695-020-04387-6 · Cited by 16

Cardiometabolic crosstalk in obesity-associated arterial hypertension

Jordan, J., & Birkenfeld, A. L. (2016) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-016-9348-1 · Cited by 17

Central serotonin participates in the anorexigenic effect of GLP-1 in rainbow trout (Oncorhynchus mykiss)

Chivite, M., Naderi, F., Conde‐Sieira, M., Soengas, J. L., López‐Patiño, M. A., & Míguez, J. M. (2021) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2021.113716 · Cited by 15

Knowledge Domain and Emerging Trends of Glucagon-Like Peptide 1 Receptor Agonists in Cardiovascular Research: A Bibliometric Analysis

Shou, X., Wang, Y., Duan, C., Yuan, G., Wei, N., Yang, Y., & Hu, Y. (2022) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2022.101194 · Cited by 16

Glucagon-like peptide-1 reduces contractile function and fails to boost glucose utilization in normal hearts in the presence of fatty acids

Nguyễn, T. D., Shingu, Y., Amorim, P., Schwarzer, M., & Doenst, T. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.07.018 · Cited by 15

Role of glucagon-like peptide-1 and its agonists on early prevention of cardiac remodeling in type 1 diabetic rat hearts

Barakat, G. M., Nuwayri‐Salti, N., Kadi, L., Bitar, K. M., Al-Jaroud, W., & Bikhazi, A. B. (2011) · General Physiology and Biophysics · doi:10.4149/gpb_2011_01_34 · Cited by 15

Protective Effects of Incretin Against Age-Related Diseases

Zhang, D., Ma, M., & Liu, Y. (2019) · Current Drug Delivery · doi:10.2174/1567201816666191010145029 · Cited by 15

Potential role of TCF7L2 gene variants on cardiac sympathetic/parasympathetic activity

Boccardi, V., Ambrosino, I., Papa, M., Fiore, D., Rizzo, M. R., Paolisso, G., & Barbieri, M. (2010) · European Journal of Human Genetics · doi:10.1038/ejhg.2010.117 · Cited by 15

Protein kinase Cβ mediates downregulated expression of glucagon-like peptide-1 receptor in hypertensive rat renal arteries

Liu, L., Liu, J., Gao, Y., Ng, C., Yu, X., Dou, D., & Huang, Y. (2015) · Journal of Hypertension · doi:10.1097/hjh.0000000000000480 · Cited by 14

Brain α4β2 nicotinic acetylcholine receptors are involved in the secretion of noradrenaline and adrenaline from adrenal medulla in rats.

Shimizu, T., Tanaka, K., Hasegawa, T., & Yokotani, K. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.12.034 · Cited by 14

Activation of PPG neurons following acute stressors differentially involves hindbrain serotonin in male rats

Leon, R. M., Borner, T., Stein, L., Urrutia, N. A., Jonghe, B. D. D., Schmidt, H. D., & Hayes, M. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108477 · Cited by 14

Exendin-4 attenuates ischemia-induced ventricular arrhythmias in rats

Kai, Z., Wu, Y., Lin, Z., Jie, G., Jin, D., & Zhiqiang, C. (2013) · Cardiology Journal · doi:10.5603/cj.2013.0006 · Cited by 14

Cardiovascular effects of GLP-1 receptor agonism

Winquist, R. J., & Gribkoff, V. K. (2022) · Advances in pharmacology · doi:10.1016/bs.apha.2022.02.005 · Cited by 14

Increased insulin clearance in mice with double deletion of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors

Tura, A., Bizzotto, R., Yamada, Y., Seino, Y., Pacini, G., & Åhrén, B. (2018) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00181.2017 · Cited by 13

Glucagon-Like Peptide-1 and its Cardiovascular Effects

Heo, K., Fujiwara, K., & Abe, J. (2012) · Current Atherosclerosis Reports · doi:10.1007/s11883-012-0265-9 · Cited by 13

Hyperglycemia after protein ingestion concurrent with injection of a GLP-1 receptor agonist in rats: a possible role for dietary peptides

Aziz, A. A., Anderson, G. H., Giacca, A., & Cho, F. (2005) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00850.2004 · Cited by 12

Determining the Effects of Combined Liraglutide and Phentermine on Metabolic Parameters, Blood Pressure, and Heart Rate in Lean and Obese Male Mice

Simonds, S. E., Pryor, J. T., Koegler, F. H., Buch-Rasmussen, A. S., Kelly, L. E., Grove, K. L., & Cowley, M. A. (2019) · Diabetes · doi:10.2337/db18-1149 · Cited by 13

Downstream interaction by glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonism is required for synergistic effects on body weight

Feetham, C. H., Ai, M., Culotta, I., Costa, A., Hunter, J., Brown, R. A., Coşkun, T., Emmerson, P. J., D’Agostino, G., & Luckman, S. M. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102214 · Cited by 12

Therapeutic potential of spinal GLP-1 receptor signaling

Zhang, D., & Lv, G. (2018) · Peptides · doi:10.1016/j.peptides.2018.01.003 · Cited by 13

Incretin-based therapy: a new horizon in diabetes management

Zarei, M., Vaighan, N. S., Farjoo, M. H., Talebi, S., & Zarei, M. (2024) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01479-3 · Cited by 12

Glucagon‐Like Peptide‐1 Links Ingestion, Homeostasis, and the Heart

Krieger, J., Daniels, D., Lee, S. J., Mastitskaya, S., & Langhans, W. (2024) · Comprehensive physiology · doi:10.1002/cph4.7 · Cited by 14

Management of the Patient With Diabetes and Coronary Artery Disease: A Contemporary Review

Raymond, T. E., Raymond, R. E., & Lincoff, A. M. (2013) · Future Cardiology · doi:10.2217/fca.13.22 · Cited by 11

Immunohistochemical determination of the site of hypotensive effects of glucagon-like peptide-2 in the rat brain

Sasaki‐Hamada, S., Okada, S., Ito, K. L., Iwai, T., & Oka, J. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.03.032 · Cited by 11

Centrally located GLP-1 receptors modulate gastric slow waves and cardiovascular function in ferrets consistent with the induction of nausea

Lu, Z., Yeung, C.-K., Lin, G., Yew, D. T. W., Andrews, P. L. R., & Rudd, J. A. (2017) · Neuropeptides · doi:10.1016/j.npep.2017.04.006 · Cited by 13

Simultaneous GLP-1 receptor activation and angiotensin receptor blockade increase natriuresis independent of altered arterial pressure in obese OLETF rats

Rodríguez, R., Moreno, M., Lee, A. Y., Godoy-Lugo, J. A., Nakano, D., Nishiyama, A., Parkes, D. G., Awayda, M. S., & Ortiz, R. M. (2018) · Hypertension Research · doi:10.1038/s41440-018-0070-0 · Cited by 11

Signaling Mechanism for Modulation by GLP-1 and Exendin-4 of GABA Receptors on Rat Retinal Ganglion Cells

Zhang, T., Ruan, H.-Z., Wang, Y., Shao, Y., Zhou, W., Weng, S.-J., & Zhong, Y. (2022) · Neuroscience Bulletin · doi:10.1007/s12264-022-00826-9 · Cited by 11

Novel role for the incretins in blood pressure regulation

Yerram, P., & Whaley‐Connell, A. T. (2012) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e328356bccd · Cited by 10

Accentuated early postprandial satiety in people with spinal cord injury versus able-bodied controls

Fenton, J. M., King, J. A., Hoekstra, S. P., Willis, S. A., Ogawa, T., & Goosey-Tolfrey, V. L. (2021) · Appetite · doi:10.1016/j.appet.2021.105628 · Cited by 10

Beneficial Influence of Exendin-4 on Specific Organs and Mechanisms Favourable for the Elderly with Concomitant Obstructive Lung Diseases

Figat, M., Kardas, G., Kuna, P., & Panek, M. (2022) · Brain Sciences · doi:10.3390/brainsci12081090 · Cited by 10

Lipid-Induced Peroxidation in the Intestine Is Involved in Glucose Homeostasis Imbalance in Mice

Sérino, M., Waget, A., Marsollier, N., Masseboeuf, M., Payros, G., Gallou‐Kabani, C., Denom, J., Lacombe, A., Thiers, J., Nègre‐Salvayre, A., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021184 · Cited by 10

Effects of incretins on blood pressure: A promising therapy for type 2 diabetes mellitus with hypertension

Wang, B., Ni, Y., ZHONG, J., & Sun, F. (2011) · Journal of Diabetes · doi:10.1111/j.1753-0407.2011.00167.x · Cited by 10

Exploiting the pleiotropic actions of GLP-1 for the management of type 2 diabetes mellitus and its complications

Giorgino, F., Natalicchio, A., Leonardini, A., & Laviola, L. (2007) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2007.09.022 · Cited by 10

GLP-1 (7–36) amide restores myocardial insulin sensitivity and prevents the progression of heart failure in senescent beagles

Chen, M., Angeli, F. S., Shen, Y., & Shannon, R. P. (2014) · Cardiovascular Diabetology · doi:10.1186/s12933-014-0115-x · Cited by 9

Glucagon-like peptide 1: continued advances, new targets and expanding promise as a model therapeutic

Aulinger, B., & D'Alessio, D. (2007) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e328013e79e · Cited by 8

Interactions between antidiabetes medications and heart–brain axis

Ong, L. T., & Sia, C. (2024) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000896 · Cited by 8

Mechanism of and strategy to mitigate liraglutide-mediated positive chronotropy

Jøns, C., Porta‐Sánchez, A., Lai, P. F. H., Wauchop, M., Massé, S., Azam, M. A., Asta, J. A., Rose, R. A., & Nanthakumar, K. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119815 · Cited by 8

ROLE OF BRAIN PROSTANOIDS IN GLUCAGON‐LIKE PEPTIDE‐1‐INDUCED CENTRAL ACTIVATION OF SYMPATHO‐ADRENOMEDULLARY OUTFLOW IN RATS

Arai, J., Okada, S., Yamaguchi, N., Shimizu, T., Sasaki, T., Yorimitsu, M., Wakiguchi, H., & Yokotani, K. (2008) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2008.04957.x · Cited by 8

Effects on repetitive 24-hour ambulatory blood pressure in subjects with type II diabetes randomized to liraglutide or glimepiride treatment both in combination with metformin: a randomized open parallel-group study

JENDLE, J. H., Fang, X. L., Cao, Y., Bojö, L., Nilsson, B., Hedberg, F., Santos‐Pardo, I., & Nyström, T. (2018) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2018.02.003 · Cited by 8

Effect of liraglutide on neural and peripheral markers of metabolic function during antipsychotic treatment in rats

Babic, I., Sellers, D., Else, P. L., Nealon, J. R., Osborne, A. L., Pai, N. B., & Weston–Green, K. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120981377 · Cited by 9

Insulin Resistance and Hypertension

Shankar, S. S., & Steinberg, H. O. (2012) · Humana Press eBooks · doi:10.1007/978-1-60761-548-4_12 · Cited by 8

Unraveling the safety profile of GLP-1 receptor agonists: Mechanistic insights with a focus on semaglutide

He, X., Zhao, Z., Sun, Y., & Jiang, X. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118163 · Cited by 8

Bolus Injection of Liraglutide Raises Plasma Glucose in Normal Rats by Activating Glucagon-like Peptide 1 Receptor in the Brain

Hsu, C.-C., Cheng, J., Hsu, P. H., Li, Y., & Cheng, K. (2022) · Pharmaceuticals · doi:10.3390/ph15070904 · Cited by 7

Incretin-Based Therapy for Type 2 Diabetes Mellitus

Hartman, I., Rojas, E., & Rodríguez-Molina, D. (2013) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e318235f27d · Cited by 8

Effect of race on cardiometabolic responses to once-weekly exenatide: insights from the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)

Davis, T. M. E., Giczewska, A., Lokhnygina, Y. V., Mentz, R. J., Sattar, N. A., Holman, R. R., & for the EXSCEL Study Group (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01555-z · Cited by 7

Gastric myoelectric activity during cisplatin-induced acute and delayed emesis reveals a temporal impairment of slow waves in ferrets: effects not reversed by the GLP-1 receptor antagonist, exendin (9-39)

Lu, Z., Ngan, M. P., Lin, G., Yew, D. T. W., Fan, X., Andrews, P. L. R., & Rudd, J. A. (2017) · Oncotarget · doi:10.18632/oncotarget.21859 · Cited by 7

The role of glucagon-like peptide-1/GLP-1R and autophagy in diabetic cardiovascular disease

Guo, Z. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00609-1 · Cited by 7

Neural Regulation of Blood Glucose in Acute Stress: A Report on Research Supported by Pathway to Stop Diabetes

Stanley, S. A. (2025) · Diabetes · doi:10.2337/dbi24-0051 · Cited by 9

DPP-4 inhibitors and heart failure: a potential role for pharmacogenomics

Krittanawong, C., Xanthopoulos, A. V., Kitai, T., Branis, N. M., Zhang, H., & Kukin, M. L. (2017) · Heart Failure Reviews · doi:10.1007/s10741-017-9655-y · Cited by 6

Don't Play with Your Nodule: Case Report of Tachycardia and Other Adverse Reactions from Manipulation of an Exenatide Injection Site Nodule

Sandman, C., Krainin, B. M., & Roper, J. (2018) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2018.01.022 · Cited by 6

Diabetes, and its treatment, as an effector of autonomic nervous system circuits and its functions

Espinoza, L., & Boychuk, C. R. (2020) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2020.06.006 · Cited by 6

Uncertainties around incretin-based therapies: A literature review

Tulaihi, B. A., & Alhabib, S. M. (2015) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2015.06.009 · Cited by 6

The non-glycemic effects of incretin therapies on cardiovascular outcomes, cognitive function and bone health

Hanna, A., Connelly, K. A., Josse, R. G., & McIntyre, R. S. (2014) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2015.972370 · Cited by 6

Potential Cardiovascular Effects of the Glucagon-like Peptide-1 Receptor Agonists

CHILTON, R. J. (2015) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.1000483 · Cited by 4

Effectiveness of Exenatide in Asian Indians in a Clinical Care Setting

Suthakaran, C., Fathima, M., Anjana, R. M., Ranjit Unnikrishnan, I., & Mohan, V. (2010) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2010.0033 · Cited by 5

The effects of DPP4 inhibitors on the levels of plasma catecholamines and their metabolites in patients with type 2 diabetes

Kim, T. H., Lee, K., Park, I. B., Choi, C. S., Ahn, T. H., & Lee, D. H. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107832 · Cited by 5

Oxyntomodulin reduces expression of glucagon-like peptide 1 receptor in the brainstem of chickens

Moghaddam, A., Yaghoobi, M. M., Jonaidi, H., Mahani, M. T., & Sepehri, H. (2009) · Journal of Animal Physiology and Animal Nutrition · doi:10.1111/j.1439-0396.2009.00925.x · Cited by 5

Exendin-4 Exacerbates Burn-Induced Morbidity in Mice by Activation of the Sympathetic Nervous System

Ji, X.-J., Hao, J.-W., Li, G., Dong, N., Wang, X., Zhou, M., Zhang, Q., & Yao, Y.-M. (2019) · Mediators of Inflammation · doi:10.1155/2019/2750528 · Cited by 5

Liraglutide increases 24-h heart rate by reducing the cardiac parasympathetic activity of patients with type 2 diabetes: power spectral analysis of heart rate variability on 24-h Holter ECG recordings

Hara, K., Aso, Y., Komatsu, T., Nakamachi, T., Sakai, Y., Takayanagi, K., Kasai, K., & Inukai, T. (2014) · Diabetology International · doi:10.1007/s13340-014-0170-2 · Cited by 4

Intact neural system of the portal vein is important for maintaining normal glucose metabolism by regulating glucagon-like peptide-1 and insulin sensitivity

Trung, V. N., Yamamoto, H., Yamaguchi, T., Murata, S., Aimi, Y., Kuwahara, A., & Tani, T. (2013) · Peptides · doi:10.1016/j.peptides.2013.12.003 · Cited by 4

Healthy lifestyle and glucagon-like peptide-1 in young and healthy adults: A population-based study

Krisai, P., Aeschbacher, S., Repilado, F. J. R., Schoen, T., Reusser, A., Meier, M., Todd, J. A., Estis, J., Risch, M., Risch, L., et al. (2017) · Preventive Medicine · doi:10.1016/j.ypmed.2017.05.025 · Cited by 4

Effects of Liraglutide on Left Ventricular Function: A Meta-Analysis of Randomized, Placebo-Controlled Trials

Zhong, Z., Chen, K., Zhao, Y., & Xia, S. (2021) · International Journal of Endocrinology · doi:10.1155/2021/9993229 · Cited by 4

Disruption of Glucagon-Like Peptide 1 Signaling in Sim1 Neurons Reduces Physiological and Behavioral Reactivity to Acute and Chronic Stress

Ghosal, S., Packard, A. E. B., Mahbod, P., McKlveen, J. M., Seeley, R. J., Myers, B., Ulrich‐Lai, Y. M., Smith, E. P., D’Alessio, D. A., & Herman, J. P. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.1104-16.2016 · Cited by 66

The incretin system in type 2 diabetes mellitus: cardiovascular effects

Sukhareva, O. Y., Шмушкович, И. А., Shestakova, E. A., & Shestakova, M. V. (2013) · Problems of Endocrinology · doi:10.14341/probl201258633-42 · Cited by 5

Effects of tirzepatide, a dual GIP and GLP-1 receptor agonist, on blood pressure, cardiac function, and sympathetic nervous system in stroke-prone spontaneously hypertensive rats

Ono, Y. O. I., Shinohara, K., Nakashima, H., Miyamoto, R., Hara, A., Ikeda, S., Matsumoto, S., Yoshida, D., Nakashima, R., Matsushima, S., et al. (2026) · Hypertension Research · doi:10.1038/s41440-026-02632-6 · Cited by 3

From Satiety to Substance Use: Neural Mechanisms of Glucagon-Like Peptide-1 Signaling in Appetite and Reward

Baumer-Harrison, C., Graham, M., Jonghe, B. C. D., & Hayes, M. R. (2026) · Biological Psychiatry · doi:10.1016/j.biopsych.2026.06.015 · Cited by 4

Predicting response to incretin-based therapy

Kalra, S., Kalra, B., Sahay, R. K., & Agrawal, N. K. (2011) · Research and Reports in Endocrine Disorders · doi:10.2147/rred.s16282 · Cited by 3

Autonomic control and bariatric procedures

Zsombok, A. (2013) · Autonomic Neuroscience · doi:10.1016/j.autneu.2013.03.002 · Cited by 3

Glucagon-like peptide-1 and related agents: Novel anti-arrhythmic agents during myocardial ischemia and reperfusion

Hu, X., Yang, X., & Jiang, H. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.04.064 · Cited by 3

Gastrointestinal signalling peptides in obesity

Nogueiras, R., Caton, S. J., Pérez–Tilve, D., Bidlingmaier, M., & Tschöp, M. H. (2006) · Drug Discovery Today Disease Mechanisms · doi:10.1016/j.ddmec.2006.11.013 · Cited by 3

Postprandial Hypotension—Methods for the Evaluation and Management

Ishikawa, J., Toba, A., Futami, S., & Harada, K. (2026) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/ggi.70456 · Cited by 2

Neural mechanisms underlying blood pressure dynamics and cardiovascular control

Matić, Z., Catrambone, V., & Valenza, G. (2026) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00803.2025 · Cited by 3

The effects of glucagon-like peptide-1 receptor agonists on sympathetic neuron activity

Koyanagi, Y., Iigaya, K., Ikeda, K., Onimaru, H., & Izumizaki, M. (2026) · Hypertension Research · doi:10.1038/s41440-026-02633-5 · Cited by 3

Effects of Glucagon-Like Peptide-1 on Arteriovenous Fistula Remodelling and Vascular Smooth Muscle Cell Phenotype Switching in Diabetic Rats

Roan, J., & Tseng, W. (2016) · Cardiovascular Pharmacology Open Access · doi:10.4172/2329-6607.1000169 · Cited by 2

Biological activity studies of the novel glucagon-like peptide-1 derivative HJ07

Han, J. D. J., Sun, L., Qian, H., & Huang, W. (2014) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(14)60093-5 · Cited by 2

GLP-1 Receptor Agonists for the Treatment of Diabetes and Obesity

Palani, A., Zhou, Y., Halleck, M. M., & Carrington, P. E. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.13765-5 · Cited by 2

Early resuscitation with exendin-4 alleviates acute lung injury after hemorrhagic shock in rats

Song, X., Chen, G., Luo, X., You, G., Yin, Y., Wang, Y., Zhao, L., & Zhou, H. M. (2017) · Journal of Surgical Research · doi:10.1016/j.jss.2017.04.004 · Cited by 2

Does endogenous GLP-1 affect resting energy expenditure and fuel selection in overweight and obese adults?

Poggiogalle, E., Donini, L. M., Chiesa, C., Pacifico, L., Lenzi, A., Perna, S., Faliva, M. A., Naso, M., & Rondanelli, M. (2017) · Journal of Endocrinological Investigation · doi:10.1007/s40618-017-0764-1 · Cited by 2

POTENTIAL ROLE OF GLP-1 RECEPTOR AGONIST IN A RAT MODEL OF CARDIO-RENAL SYNDROME TYPE-3: EFFECTS ON OXIDATIVE, INFLAMMATORY AND INOS EXPRESSION AXIS

Abood, A., Awad, H., & Hassan, S. M. (2021) · Ain Shams Medical Journal · doi:10.21608/asmj.2021.167313 · Cited by 2

Brainstem-Hypothalamic Neuropeptides and the Regulation of Feeding

Luckman, S. M. (2007) · Elsevier eBooks · doi:10.1016/b978-012370633-1/50005-0 · Cited by 2

Addiction as a cardiometabolic disease: a neurocardiometabolic framework and the emerging role of GLP-1 receptor therapies

Seijas‐Amigo, J., Salgado‐Barreira, Á., Eiras, S., Arias-Rivas, S., Rodríguez-Carnero, G., Rodríguez‐Mañero, M., & González‐Juanatey, J. R. (2026) · European Heart Journal Open · doi:10.1093/ehjopen/oeag101 · Cited by 1

Effets cardiovasculaires des inhibiteurs de la DPP-4

Vergès, B. L. (2013) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(13)70563-7 · Cited by 1

The Incretin System and Cardiovascular Risk: Effects of Incretin-Targeted Therapies

Mundil, D., Noyan-Ashraf, M. H., & Husain, M. (2010) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-010-0141-5 · Cited by 1

Inkretine: Gibt es kardiovaskuläre Effekte?

Gallwitz, B. (2010) · Herz · doi:10.1007/s00059-010-3333-3 · Cited by 1

DPP-4-Hemmer und GLP-1-Rezeptor-Agonisten

Nauck, M. A., Aziz, M. S. A. E., & Meier, J. J. (2016) · Der Diabetologe · doi:10.1007/s11428-016-0083-8 · Cited by 1

Incretin-based therapies for the failing heart

Ussher, J. R., & Campbell, J. E. (2016) · Cardiovascular Endocrinology · doi:10.1097/xce.0000000000000086 · Cited by 1

Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1-(7-36) amide in rats

Barragan, J. M., Rodrı́guez, R. E., & Blázquez, E. (1994) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1994.266.3.e459 · Cited by 177

Glucagon-Like Peptide-1-Responsive Catecholamine Neurons in the Area Postrema Link Peripheral Glucagon-Like Peptide-1 with Central Autonomic Control Sites

Yamamoto, H., Kishi, T., Lee, C. E., Choi, B. J., Fang, H., Hollenberg, A. N., Drucker, D. J., & Elmquist, J. K. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-07-02939.2003 · Cited by 294

Comment on “The effects of glucagon-like peptide-1 receptor agonists on sympathetic neuron activity”

Liu, Y. (2026) · Hypertension Research · doi:10.1038/s41440-026-02681-x · Cited by 1

GLP-1 receptor stimulation depresses heart rate variability and inhibits neurotransmission to cardiac vagal neurons

Griffioen, K. J. S., Wan, R., Okun, E., Wang, X., Lovett-Barr, M. R., Li, Y., Mughal, M. R., Mendelowitz, D., & Mattson, M. P. (2010) · Cardiovascular Research · doi:10.1093/cvr/cvq271 · Cited by 110

Abstract 13078: Central Glucagon-like peptide-1 Receptor Activation Counteracts Hypertension with Suppression of Sympathetic Nerve Activity in Spontaneously Hypertensive Rats

Katsurada, K., Maejima, Y., Nakata, M., Yada, T., & Kario, K. (2014) · Circulation